Table 2.

AEs experienced during acalabrutinib treatment (≥15% any grade) for all treated patients (N = 33)

AEn (%)
Any gradeGrade 1Grade 2Grade 3Grade 4
Diarrhea19 (58)15 (45)4 (12)00
Headache13 (39)9 (27)4 (12)00
Cough11 (33)6 (18)5 (15)00
Weight increased10 (30)6 (18)3 (9)1 (3)0
Nausea9 (27)6 (18)2 (6)1 (3)0
Contusion8 (24)5 (15)3 (9)00
Upper respiratory tract infection8 (24)2 (6)5 (15)1 (3)0
Arthralgia7 (21)6 (18)1 (3)00
Pyrexia7 (21)5 (15)1 (3)1 (3)0
Vomiting7 (21)5 (15)2 (6)00
Fatigue6 (18)3 (9)3 (9)00
Myalgia6 (18)2 (6)3 (9)00
Rash6 (18)5 (15)1 (3)00
Constipation5 (15)4 (12)1 (3)00
Dizziness5 (15)3 (9)2 (6)00
Ecchymosis5 (15)4 (12)1 (3)00
Fall5 (15)3 (9)2 (6)00
Noncardiac chest pain5 (15)3 (9)1 (3)1 (3)0